Skip to content

Efficacy of lafurtidine in gastric mucosal lesions with acute gastritis / chronic gastritis: a randomized controlled study with rebaate

Efficacy of lafurtidine in gastric mucosal lesions with acute gastritis / chronic gastritis: a randomized controlled study with rebaate

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300070452
Enrollment
Unknown
Registered
2023-04-12
Start date
2023-05-01
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastritis

Interventions

treatment group:Lafurtidine treatment
control group:Rebapide treatment

Sponsors

Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 18 and 65 years; 2. No gender limit; 3. Clinical symptoms are typical symptoms of acute gastritis such as upper abdominal pain, fullness, nausea, vomiting and loss of appetite; 4. The patient was diagnosed with acute aggravation of acute gastritis/chronic gastritis by endoscopy combined with symptoms and medical history; 5. Consent to investigational treatment options; 6. Voluntarily sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with a history of peptic ulcer or reflux esophagitis; 2. Patients with a history of gastrointestinal surgery; 3. Patients with a history of gastrointestinal malignancy; 4. Used drugs that affected the study, such as PPIs, H2RA, mucosal protector, etc., within 2 weeks before entering the study; 5. Patients who required glucocorticoids, NSAIDs, or antithrombotic drugs during the study period; 6. Helicobacter pylori positive patients; 7. Pregnant or lactating patients; 8. Women of childbearing age who do not use contraception; 9. Patients with serious diseases of the blood system, liver, kidney, heart, lung, hematopoietic system and endocrine system; 10. Patients with contraindications for lafurtidine or rebapide; 11. Patients taking drugs that may interact with each other; 12. Patients with mental illness or addicted to alcohol and drugs; 13. Patients who are participating in other clinical studies; 14. Patients with communication and coordination disorders.

Design outcomes

Primary

MeasureTime frame
Gastric mucosa;

Secondary

MeasureTime frame
Improvement of symptoms (upper abdominal pain, bloating, acid reflux, heartburn, belching, nausea/vomiting, loss of appetite) after 14 days of medication;

Countries

China

Contacts

Public ContactLin Rong

Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology

linrong@hust.edu.cn+86 15629180035

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026